Karras Alexandre, Guiard Elsa, Lévi Charlène, Thervet Eric
Assistance publique-Hôpitaux de Paris, hôpital Européen Georges-Pompidou, service de néphrologie, 75015 Paris, France.
Presse Med. 2012 Oct;41(10):1014-23. doi: 10.1016/j.lpm.2012.06.007. Epub 2012 Aug 17.
Granulomatosis with polyangiitis (GPA), is the recently proposed, new alternative name for Wegener's granulomatosis. It defines a systemic small-vessels vasculitis, characterized by frequent involvement of upper and lower respiratory tract. The presence of cytoplasmic-type ANCA with anti-proteinase 3 specificity is observed in more than 90% of patients with GPA but is not mandatory for the definition of the disease, which is based on clinical criteria and presence of granulomas on the tissue biopsy. Necrotizing glomerulonephritis is observed in more than 50% of patients, and has important prognostic value, requiring urgent therapeutic intervention. Classical immunosuppressive schemes used in GPA combine high-dose corticosteroids and cyclophosphamide, but recent trials have shown that rituximab offers a similar efficacy with probably less cytotoxic side-effects. The best maintenance treatment is not yet defined, but the prevention of relapses remains the main therapeutic challenge in this vasculitis.
肉芽肿性多血管炎(GPA)是最近提出的韦格纳肉芽肿的新替代名称。它定义了一种系统性小血管血管炎,其特征是上、下呼吸道经常受累。在超过90%的GPA患者中可观察到具有抗蛋白酶3特异性的胞质型抗中性粒细胞胞浆抗体(ANCA),但对于基于临床标准和组织活检中肉芽肿的存在来定义该疾病而言,它并非必需条件。超过50%的患者会出现坏死性肾小球肾炎,其具有重要的预后价值,需要紧急治疗干预。GPA中使用的经典免疫抑制方案联合了高剂量皮质类固醇和环磷酰胺,但最近的试验表明,利妥昔单抗具有相似的疗效,且细胞毒性副作用可能较小。最佳的维持治疗方案尚未确定,但预防复发仍然是这种血管炎的主要治疗挑战。